Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis

October 20, 2026

2

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Related Articles

Apple shares aren’t cheap. Here’s how to get long for less

What options traders expect from SpaceX earnings after the bell

Salesforce announces $5.66 billion deal for Braze, sending BRZE stock soaring 50%

Latest Articles

Apple shares aren’t cheap. Here’s how to get long for less

What options traders expect from SpaceX earnings after the bell

Salesforce announces $5.66 billion deal for Braze, sending BRZE stock soaring 50%

Anthropic in talks with neocloud Nscale over second multibillion-dollar deal, source tells CNBC

Investors look to earnings to reset the bull market. The key level to watch on the S&P 500